The association between platelet glycoprotein-specific antibodies and response to short-term high-dose dexamethasone with prednisone maintenance treatment in adult patients with primary immune thrombocytopenia

Figures & data

Table 1. Patient characteristics.

Characteristics	Antibody positive group (n = 72)	Antibody negative group (n = 40)	p Value
Median age (y) (range)	64 (32–75)	60 (29–74)	.739
Male/female, n	34/38	18/22	.821
Median platelet count (×10^9/L) (range)	12.5 (1–29)	18.5 (0–30)	.095
Median bleeding score (range)	1 (0-8)	1 (0-8)	.914
BMI (kg/m^2)	23.22 ± 3.43	23.17 ± 3.10	.954
Combined with IVIG, n (%)	30 (41.67)	13 (32.50)	.339
Comorbidities at diagnosis, n (%)
Diabetes	8 (11.11)	5 (12.50)	.930
Hypertension	27 (37.50)	11 (27.50)	.284
Thyroid disease	5 (6.94)	3 (7.50)	.785
Coronary heart disease	11 (15.28)	6 (15.00%)	.969
Antiplatelet antibodies, n (%)
Anti-GP IIb/IIIa positive	52 (72.22)	–	–
Anti-GP Ib/IX positive	38 (52.78)	–	–
Anti-P selectin positive	24 (33.33)	–	–

Table 2. Response to treatment in antibody positive and negative patients.

	CR, n (%)	R, n (%)	NR, n (%)	Overall response rate (%)
Antibody positive group (n = 72)	50 (69.44)*	18 (25.00)	4 (5.56)	94.44
Anti-GP IIb/IIIa (+) only	24 (80.00)*	6 (20.00)	0 (0)	100.00
Anti-GP Ib/IX (+) only	2 (50.00)	2 (50.00)	0 (0)	100.00
Anti-P selectin (+) only	2 (50.00)	2 (50.00)	0 (0)	100.00
Anti-GP IIb/IIIa (+) plus anti-GP Ib/IX (+)	10 (71.43)	0 (0)	4 (28.57)	71.43
Anti-GP Ib/IX (+) plus anti-P selectin (+)	8 (66.67)	4 (33.33)	0 (0)	100.00
Anti-GP IIb/IIIa (+) plus anti-GP Ib/IX (+) plus anti-P selectin (+)	4 (50.00)	4 (50.00)	0 (0)	100.00
Antibody negative group (n = 40)	16 (40.00)	16 (40.00)	8 (20.00)	80.00

CR: complete response; R: response; NR: no response; *indicated that p < .05 versus antibody negative group.

Table 3. The effect of baseline characteristics on treatment response by logistic regression analysis.

Variable	Univariate OR (95% CI)	p Value	Multivariate OR (95% CI)	p Value
Platelet glycoprotein-specific antibody	4.278 (1.314–13.928)	.016	4.320 (1.113–16.767)	.034
Gender	2.017 (0.656–6.197)	.221	2.690 (0.708–10.224)	.146
Age	1.052 (1.005–1.010)	.031	1.061 (1.007–1.118)	.027
BMI	0.924 (0.779–1.097)	.368	0.877 (0.713–1.079)	.216
Platelet count before treatment	0.952 (0.893–1.015)	.130	0.970 (0.898–1.047)	.436
The use of IVIG	2.283 (0.630–8.272)	.209	1.808 (0.391–8.372)	.449

OR: odd ratio; CI: confidence interval.

Data availability statement

All data generated or analyzed during this study are included in this published article.